Mol Cancer
Claims involving fat loss, obesity, glucose control, liver disease, sarcopenia, metabolism or anti-ageing could contribute to medicinal classification
Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1
GHK-Cu activates the Wnt/beta-catenin pathway that drives the anagen (growth) phase of the hair cycle, stimulates VEGF and hepatocyte growth factor for follicle health, and has been shown in clinical research to increase follicle size and density with sustained use
In human clinical use, reported side effects are generally mild and transient: Mild injection site redness or discomfort (resolves within hours) Transient nausea in some patients, particularly early in the protocol Mild dizziness or light-headedness (rare, typically dose-related) Temporary fatigue in the first few days (often a sign of active tissue remodeling) No significant systemic toxicity, organ damage, hormonal suppression, or addiction potential has been documented in the published literature